Disease landscape

Ovarian Cancer clinical trials

Get alerts when Ovarian Cancer trials change

980 active trials 554 recruiting 104 Phase 3 499 sponsors 140 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 65 of 140 changes on 20 trials

2026-08-21
Trial terminated
Trial terminated: Limited clinical activity
Trial sites reduced: 17 → 1 locations
NCT06315491 A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer · Cybrexa Therapeutics · Phase 2
2026-08-14
Trial terminated
Trial terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.
Primary endpoint(s) modified
Primary completion moved earlier: 2025-07 → 2025-04-30
Completion moved earlier: 2025-11 → 2025-04-30
NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… · NextCure, Inc. · Phase 1/2
2026-09-05
Trial terminated
Trial terminated: No accrual in one year
Primary endpoint(s) modified
Results posted: 2026-09-04
Final enrollment: 12 participants (planned 34)
Primary completion confirmed: March 2024 (last estimated June 2025)
NCT04315233 Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent… · University of Utah · Phase 1
2026-08-07
Trial terminated
Trial terminated: Study terminated due to various reasons impacting the feasibility of future clinical development
Primary completion moved earlier: 2025-12 → 2025-01-01
Completion moved earlier: 2025-12 → 2025-01-01
NCT05226507 A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… · Nuvectis Pharma, Inc. · Phase 1
2026-08-25
Trial terminated
Primary completion moved earlier: 2029-12-31 → 2026-07-01
Completion moved earlier: 2030-12-31 → 2026-07-31
NCT03362606 Engineered Immune Effectors Against Ovarian Cancer · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-08-25
Trial terminated
Primary completion moved earlier: 2028-09-30 → 2026-07-01
Completion moved earlier: 2029-12-31 → 2026-07-31
NCT03184753 Genetically Modified T Cells Against Ovarian Cancer · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-09-05
Primary completion pushed: 2027-02 → 2029-06
Primary endpoint(s) modified
Enrollment increased: 495 → 575 participants
Interventions modified
Completion pushed: 2027-04 → 2029-06
Trial arms changed: 9 → 11
NCT06400472 A Study of Sofe-M in Participants With Selected Advanced Solid Tumors · Eli Lilly and Company · Phase 1
2026-09-04
Primary completion pushed: 2026-04 → 2026-12
Enrollment closed, study ongoing
Completion pushed: 2026-04 → 2026-12
NCT06337084 Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors · Monopar Therapeutics · Phase 1
2026-09-03
Primary completion pushed: 2027-06-30 → 2029-09-29
Completion pushed: 2027-06-30 → 2029-09-29
NCT07167433 Observational, Bi-directional (Prospective and Retrospective) Study for Patients With… · AstraZeneca
2026-08-22
Primary completion pushed: 2026-06 → 2027-02
Enrollment closed, study ongoing
Completion moved earlier: 2027-06 → 2027-02
NCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab… · AbbVie · Phase 2
2026-08-19
Primary completion pushed: 2026-11-30 → 2027-02-28
Completion pushed: 2026-11-30 → 2027-02-28
NCT07469202 CYTALUX Dose Extension Study · On Target Laboratories, LLC · Phase 4
2026-08-12
Primary completion pushed: 2025-06-30 → 2026-12-30
Sponsor changed: Evopoint Biosciences Inc. → Astellas Pharma Global Development, Inc.
Enrollment closed, study ongoing
Completion pushed: 2025-12-31 → 2027-06-30
NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. · Astellas Pharma Global Development, Inc. · Phase 1/2
2026-08-22
Primary completion pushed: 2026-08-26 → 2028-08-26
Completion pushed: 2026-08-26 → 2028-08-26
NCT05554367 Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial · National Cancer Institute (NCI) · Phase 2
2026-09-03
Primary endpoint(s) modified
Enrollment increased: 460 → 605 participants
Interventions modified
Completion pushed: 2029-03-27 → 2031-02-07
Trial arms changed: 10 → 14
NCT06843447 A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) · Merck Sharp & Dohme LLC · Phase 1/2
2026-09-03
Primary endpoint(s) modified
Trial completed
Primary completion confirmed: June 2026 (last estimated June 2027)
NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in… · Sensei Biotherapeutics, Inc. · Phase 1/2
2026-08-28
Primary completion pushed: 2026-07-07 → 2028-07-07
Completion pushed: 2027-07-07 → 2028-07-07
NCT07078409 Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology · Abramson Cancer Center at Penn Medicine
2026-08-21
Primary completion pushed: 2026-06 → 2026-10
Completion pushed: 2026-09 → 2026-12
NCT03355976 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas · Brown University · Phase 2
2026-08-14
Primary completion pushed: 2026-07-01 → 2031-07-01
Completion pushed: 2027-07-01 → 2032-07-01
NCT06040970 Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent… · Icahn School of Medicine at Mount Sinai · Phase 1/2
2026-08-22
Primary completion pushed: 2026-04-01 → 2028-04-01
Completion pushed: 2026-04-01 → 2028-04-01
NCT04310826 Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian… · M.D. Anderson Cancer Center
2026-08-21
Primary completion pushed: 2026-06-10 → 2026-12-06
Enrollment closed, study ongoing
Completion pushed: 2026-08-10 → 2027-01
NCT06459271 Feasibility of CALM in Patients With Ovarian Cancer · University Health Network, Toronto

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-24 NCT07782164 Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) Amsterdam UMC, location VUmc new
2026-08-21 NCT07778498 A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or… Phrontline Biopharma new Phase 1/2
2026-08-19 NCT07772882 Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant… Rebecca Arend new Phase 1
2026-08-14 NCT07764744 Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2… Weill Medical College of Cornell University new
2026-08-13 NCT07764133 Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a… University of Tennessee Graduate School of Medicine new
2026-08-12 NCT07761416 Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention St. Joseph's Healthcare Hamilton new Early Phase 1
2026-08-11 NCT07757711 Implementation of New Models of Ovarian Carcinoma Resistant to Therapy Mario Negri Institute for Pharmacological Research new
2026-08-10 NCT07755436 Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and… ArriVent BioPharma, Inc. new Phase 1
2026-08-07 NCT07752875 A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53… LG Chem new Phase 1/2

Active trials by phase

Early Phase 1
16
Phase 1
179
Phase 1/2
110
Phase 2
210
Phase 2/3
16
Phase 3
88
Phase 4
7
Not charted: 354 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 980

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT06412120 Study Evaluating Safety, Tolerability, and Metabolism of Niraparib University of Miami Recruiting 2026-08-05
NCT05606692 Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) Kaohsiung Medical University Chung-Ho Memorial Hospital Recruiting 2023-05-30
NCT07469202 CYTALUX Dose Extension Study On Target Laboratories, LLC Not Yet Recruiting 2026-08-18
NCT07075250 Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With… Peking University People's Hospital Not Yet Recruiting 2025-07-20
NCT06972693 NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma European Institute of Oncology Active, Not Recruiting 2025-05-15
NCT06887933 A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With… GlaxoSmithKline Not Yet Recruiting 2025-03-21
NCT06871787 Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses… Istanbul University Not Yet Recruiting 2025-03-14
Phase 3
NCT06824467 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870)… Merck Sharp & Dohme LLC Recruiting 2026-09-03
NCT07318558 A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… Merck Sharp & Dohme LLC Recruiting 2026-09-03
NCT07564141 Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to… Genmab Recruiting 2026-09-01
NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's… Genelux Corporation Recruiting 2026-08-26
NCT07213804 A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With… Eli Lilly and Company Recruiting 2026-08-21
NCT06072781 A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous… Verastem, Inc. Recruiting 2026-08-14
NCT07604766 An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of… Genmab Recruiting 2026-08-14
NCT07546500 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With… K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Recruiting 2026-08-12
NCT06580314 Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian… NRG Oncology Recruiting 2026-08-07
NCT07214779 Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants… Incyte Corporation Recruiting 2026-08-06
NCT06476184 Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly… ARCAGY/ GINECO GROUP Recruiting 2026-08-04
NCT06915025 Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/… Imunon Recruiting 2026-08-04
NCT07225270 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… Genmab Recruiting 2026-08-04
NCT07218809 AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low… AstraZeneca Recruiting 2026-07-21
NCT07286266 A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in… GlaxoSmithKline Recruiting 2026-07-15
NCT05804370 Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) NX Development Corp Recruiting 2026-07-14
NCT06994195 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients… Sichuan Baili Pharmaceutical Co., Ltd. Recruiting 2026-07-07
NCT06819007 Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for… Daiichi Sankyo Recruiting 2026-07-02
See all 980 active Ovarian Cancer trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (44) · M.D. Anderson Cancer Center (36) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (25) · AstraZeneca (19) · Memorial Sloan Kettering Cancer Center (17) · AbbVie (13) · Fudan University (11) · Shanghai Gynecologic Oncology Group (11) · University Health Network, Toronto (11) · Mayo Clinic (10)

Get alerts when Ovarian Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free